NeoCura, as a leading AI + RNA innovative drug research and development enterprise in China, has achieved dual improvements in the efficiency and quality of drug development by relying on its self-developed AI algorithms and RNA innovative drug R&D platform. In the challenging and cutting-edge field of mRNA tumor drug research, NeoCura researchers have made several breakthrough achievements through relentless exploration and innovation. Currently, the core technology has accumulated over a hundred patent applications both domestically and internationally. The self-developed NeoCura AI ALPINE neoantigen prediction system enables high-precision screening of tumor neoantigens with a globally leading prediction accuracy rate.

Based on profound technical accumulation, NeoCura has successfully developed the groundbreaking mRNA personalized tumor neoantigen vaccine XH001, which has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to carry out clinical research. It will be used as an adjuvant treatment after radical surgery for high-risk recurrent solid tumor patients, providing a safe, effective, and affordable new treatment option for cancer patients.